Why is Divis Laboratories Ltd falling/rising?

Recent Price Movement and Market Context

Divis Laboratories has experienced a consistent downward trend over the past week, with a one-week return of -2.53%, closely mirroring the Sensex’s decline of -2.60%. Over the last month, the stock has fallen by 8.47%, again tracking the benchmark’s 8.62% drop. Year-to-date, the stock is down 8.35%, though this is notably better than the Sensex’s 13.96% decline. Despite these short-term setbacks, the stock has delivered a positive 3.46% return over the past year, outperforming the Sensex’s negative 4.30% return. The longer-term performance is even more impressive, with a three-year gain of 107.41% compared to the Sensex’s 24.29%, and a five-year return of 62.12% against the benchmark’s 46.55%.

On 02-Apr, the stock touched an intraday low of ₹5,648, representing a 4.38% drop from recent levels. It is currently trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling a bearish technical outlook. However, investor participation has increased, with delivery volumes on 01-Apr rising by 89.29% to 3.96 lakh shares compared to the five-day average, indicating heightened trading activity despite the price decline.

Fundamental Strengths Supporting the Stock

Divis Laboratories continues to demonstrate strong operational performance. The company has reported positive results for six consecutive quarters, with a profit after tax (PAT) of ₹1,872.31 crores for the nine months ended, reflecting a growth rate of 22.45%. Its return on capital employed (ROCE) for the half-year stands at an impressive 20.94%, while quarterly PBDIT reached a record ₹890 crores. These figures underscore the company’s efficient management and operational excellence.

Financially, Divis maintains a low debt-to-equity ratio averaging zero, indicating a conservative capital structure. Its return on equity (ROE) is high at 17.24%, signalling effective utilisation of shareholder funds. Institutional investors hold a significant 39.36% stake, suggesting confidence from sophisticated market participants who typically conduct thorough fundamental analysis.

With a market capitalisation of ₹1,60,635 crores, Divis Laboratories is the second-largest company in its sector, accounting for nearly 7% of the sector’s market value. Its annual sales of ₹10,314 crores represent over 2% of the industry, highlighting its substantial presence and influence.

Valuation Concerns Weighing on the Stock

Despite these positives, the stock’s recent decline can be attributed largely to valuation pressures. The company’s price-to-book value stands at a steep 10.1, indicating that the stock is trading at a significant premium relative to its peers and historical averages. This elevated valuation may be deterring some investors, especially given the company’s modest long-term growth rates.

Over the past five years, Divis Laboratories’ net sales have grown at an annualised rate of 9.44%, while operating profit has increased by only 4.68% annually. These growth rates, though positive, may not justify the current premium valuation in the eyes of some market participants. Furthermore, the company’s price-to-earnings-to-growth (PEG) ratio is 2.7, suggesting that the stock’s price growth is outpacing its earnings growth, which can be a red flag for value-conscious investors.

In addition, while the stock has generated a 3.46% return over the last year, its profits have risen by 22.6%, indicating a disconnect between earnings growth and share price appreciation. This divergence may be contributing to the recent selling pressure as investors reassess the stock’s risk-reward profile.

Conclusion: Balancing Strong Fundamentals with Market Realities

Divis Laboratories Ltd’s recent share price decline reflects a complex interplay between its strong operational fundamentals and elevated valuation metrics. While the company continues to deliver robust earnings growth, high returns on equity, and solid institutional backing, its premium valuation and relatively modest long-term sales growth have prompted profit-taking and cautious sentiment among investors.

For investors, the stock’s long-term outperformance and consistent quarterly results remain attractive. However, the current technical weakness and valuation concerns suggest a need for careful analysis before initiating or adding to positions. The stock’s liquidity and rising investor participation indicate that it remains actively traded, offering opportunities for those who can navigate its short-term volatility.

Get 2 full years of MojoOne Premium for only Rs. 12,999. Subscribe for 1 year and we'll add another year FREE. Offer valid for a limited time. Start Saving Now →